Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: A09AA02

Enzepi(pancreas powder)

Exocrine Pancreatic Insufficiency

Marketing Authorisation Holder: Allergan Pharmaceuticals International Limited

EMA Authorisation: 29/06/2016

INN: pancreas powder

Indication

Pancreatic enzyme replacement treatment in exocrine pancreatic insufficiency due to cystic fibrosis or other conditions (e.g. chronic pancreatitis, post pancreatectomy or pancreatic cancer).Enzepi is indicated in infants, children, adolescents and adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Enzepi — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.